Header

UZH-Logo

Maintenance Infos

Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration


Nguyen, Vuong; Daien, Vincent; Guymer, Robyn; Young, Stephanie; Hunyor, Alex; Fraser-Bell, Samantha; Hunt, Adrian; Gillies, Mark C; Barthelmes, Daniel (2019). Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration. Ophthalmology, 126(1):64-74.

Abstract

PURPOSE To explore various methods for assessing the early response to vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration and investigate their association with 3 year visual acuity (VA) outcomes.
DESIGN Observational study from a prospectively collected registry.
PARTICIPANTS Treatment-naïve eyes in the Fight Retinal Blindness! outcomes registry that commenced anti-VEGF therapy between 1st January 2007 and 1st March 2014 that received 3 anti-VEGF injections within the first 3 months.
METHODS The early response was defined as occurring up until the 4th injection. Various early response metrics, which included both continuous and categorical variables, were explored: 1) achieving good VA (≥70 letters [20/40]), 2) absolute change in VA from baseline, 3) time to first grading of the choroidal neovascular lesion as inactive, 4) maximum rate of VA change between successive injections.
MAIN OUTCOME MEASURES Proportion of eyes achieving ≥70 letters at 3 years.
RESULTS This study included 2051 treatment-naïve eyes from 1828 patients. Achieving good vision at 3 years was significantly associated with 1) having good vision by the 4th injection (odds ratio [95% CI]: 9.8 [6.5, 14.7] for VA≥70 vs. VA<70 letters), 2) small (1-5 letters) or large (>5 letters) early VA gains (1.8 [1.2, 2.6], P = 0.002 and 1.8 [1.3, 2.5], P < 0.001 vs. eyes with early VA loss), 3) fewer injections until first grading of lesion inactivity (1.6 [1.2, 2.1], P < 0.001 for ≤3 vs. >3 injections), 4) gradual change (between -4 and 4 letters) or rapid (>5 letters) gains between successive injections (1.7 [1.1, 2.6], P = 0.015 and 1.6 [1.1, 2.3], P = 0.018 for gradual change and rapid gain vs. rapid loss). Eyes that achieved small or large early gains achieved similar vision at 3 years (65.0 and 64.7 letters respectively), and had better vision than eyes with early VA loss (57.2 letters).
CONCLUSIONS Attainment of good vision by the 4th injection was strongly associated with 3 year visual outcomes, while other early response parameters had a moderate association. The early response during the initial 3 monthly loading doses can be a useful guide for subsequent treatment decisions.

Abstract

PURPOSE To explore various methods for assessing the early response to vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration and investigate their association with 3 year visual acuity (VA) outcomes.
DESIGN Observational study from a prospectively collected registry.
PARTICIPANTS Treatment-naïve eyes in the Fight Retinal Blindness! outcomes registry that commenced anti-VEGF therapy between 1st January 2007 and 1st March 2014 that received 3 anti-VEGF injections within the first 3 months.
METHODS The early response was defined as occurring up until the 4th injection. Various early response metrics, which included both continuous and categorical variables, were explored: 1) achieving good VA (≥70 letters [20/40]), 2) absolute change in VA from baseline, 3) time to first grading of the choroidal neovascular lesion as inactive, 4) maximum rate of VA change between successive injections.
MAIN OUTCOME MEASURES Proportion of eyes achieving ≥70 letters at 3 years.
RESULTS This study included 2051 treatment-naïve eyes from 1828 patients. Achieving good vision at 3 years was significantly associated with 1) having good vision by the 4th injection (odds ratio [95% CI]: 9.8 [6.5, 14.7] for VA≥70 vs. VA<70 letters), 2) small (1-5 letters) or large (>5 letters) early VA gains (1.8 [1.2, 2.6], P = 0.002 and 1.8 [1.3, 2.5], P < 0.001 vs. eyes with early VA loss), 3) fewer injections until first grading of lesion inactivity (1.6 [1.2, 2.1], P < 0.001 for ≤3 vs. >3 injections), 4) gradual change (between -4 and 4 letters) or rapid (>5 letters) gains between successive injections (1.7 [1.1, 2.6], P = 0.015 and 1.6 [1.1, 2.3], P = 0.018 for gradual change and rapid gain vs. rapid loss). Eyes that achieved small or large early gains achieved similar vision at 3 years (65.0 and 64.7 letters respectively), and had better vision than eyes with early VA loss (57.2 letters).
CONCLUSIONS Attainment of good vision by the 4th injection was strongly associated with 3 year visual outcomes, while other early response parameters had a moderate association. The early response during the initial 3 monthly loading doses can be a useful guide for subsequent treatment decisions.

Statistics

Citations

Dimensions.ai Metrics
9 citations in Web of Science®
9 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

25 downloads since deposited on 29 Aug 2018
24 downloads since 12 months
Detailed statistics

Additional indexing

Contributors:Fight Retinal Blindness! Study Group
Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Ophthalmology Clinic
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Ophthalmology
Language:English
Date:1 January 2019
Deposited On:29 Aug 2018 12:49
Last Modified:29 Jul 2020 07:39
Publisher:Elsevier
ISSN:0161-6420
OA Status:Green
Publisher DOI:https://doi.org/10.1016/j.ophtha.2018.08.023
PubMed ID:30149035

Download

Green Open Access

Download PDF  'Projection of long-term visual acuity outcomes based on initial treatment response in neovascular age-related macular degeneration'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 555kB
View at publisher